Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
Keywords: لیپاتینیب; Trastuzumab; Lapatinib; Chemotherapy-free; HER2-enriched; Microarray; Signature; CT; chemotherapy; total HER2; (H2T); p95HER2; (p95); PP; persistence on protocol; CR; complete remission; PR; partial remission; SD; stable disease; PD; progressive disease;